Abstrakt

No-reflow phenomenon is an important complication of primary percutaneous coronary intervention. Several variants in the endothelial nitric oxide synthase gene, which reduce endothelial nitric oxide synthase activity, are a risk factor for coronary heart disease. However, its role in no-reflow phenomenon has not yet been revealed. This study aimed to investigate whether there is a relationship between endothelial nitric oxide synthase Glu298Asp gene variant and the development of coronary no-reflow phenomenon in patients with ST elevation myocardial infarction. The study was conducted among 116 patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. Group 1 included 52 ST elevation myocardial infarction patients undergoing no-reflow phenomenon as a study group. Group 2 comprised 64 ST elevation myocardial infarction patients without no-reflow phenomenon as a control group. Endothelial nitric oxide synthase was tested using polymerase chain reaction-restriction fragment length variant. The prevalence of TT genotype of endothelial nitric oxide synthase Glu298Asp gene variant was found to be significantly higher in patients developing coronary no-reflow when compared to those without no-reflow (p = 0.016; 11.54% vs. 1.56%) (OR = 10.85, 95% CI = 1.22–96.39). However, a similar association for the heterozygous GT genotype of endothelial nitric oxide synthase Glu298Asp gene variant was not observed between the two groups. The results of this preliminary study indicate that there is an association between Glu298Asp variant in endothelial nitric oxide synthase gene and the development of no-reflow phenomenon in ST elevation myocardial infarction. The presence of homozygous TT allele may contribute to tendency to the development of no-reflow phenomenon.

Przypisy

• 1. Abdel-Aziz T.A., Mohamed R.H.: Association of endothelial nit­ric oxide synthase gene polymorphisms with classical risk factors in development of premature coronary artery disease. Mol. Biol. Rep., 2013; 40: 3065–3071
  Google Scholar
• 2. Agirbasli M., Guney A.I., Ozturhan H.S., Agirbasli D., Ulucan K., Sevinc D., Kirac D., Ryckman K.K., Williams S.M.: Multifactor dimen­sionality reduction analysis of MTHFR, PAI-1, ACE, PON1 and eNOS gene polymorphisms in patients with early onset coronary artery disease. Eur. J. Cardiovasc. Prev. Rehabil., 2011; 18: 803–809
  Google Scholar
• 3. Casas J.P., Bautista L.E., Humphries S.E., Hingorani A.D.: Endot­helial nitric oxide synthase genotype and ischemic heart disease: Meta-analysis of 26 studies involving 23028 subjects. Circulation, 2004; 109: 1359–1365
  Google Scholar
• 4. Casas J.P., Cavalleri G.L., Bautista L.E., Smeeth L., Humphries S.E., Hingorani A.D.: Endothelial nitric oxide synthase gene polymorp­hisms and cardiovascular disease: A HuGE review. Am. J. Epidemiol., 2006; 164: 921–935
  Google Scholar
• 5. Eeckhout E., Kern M.J.: The coronary no-reflow phenomenon. A review of mechanisms and therapies. Eur. Heart J., 2001; 22: 729–739
  Google Scholar
• 6. Gensini G.G.: A more meaningful scoring system for determining the severity of coronary heart disease. Am. J. Cardiol., 1983; 51: 606
  Google Scholar
• 7. Gulec S., Karabulut H., Ozdemir A.O., Ozdol C., Turhan S., Altin T., Tutar E., Genc Y., Erol C.: Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development. Atherosclerosis, 2008; 198: 354–359
  Google Scholar
• 8. Gupta M.D., Akkarappatty C., Girish M.P., Kumar R., Rain M., Tyagi S., Qadar Pasha M.A.: Association between the Glu298Asp and 4b/4a polymorphisms of endothelial nitric oxide synthase and coronary slow flow in the North Indian population. Coron. Artery Dis.. 2014; 25: 192–197
  Google Scholar
• 9. Hillegass W.B., Dean N.A., Liao L., Rhinehart R.G., Myers P.R.: Tre­atment of no-reflow and impaired flow with the nitric oxide donor nitro prusside following percutaneous coronary interventions: Initial human clinical experience. J. Am. Coll. Cardiol., 2001; 37: 1335–1343
  Google Scholar
• 10. Isordia-Salas I., Leaños-Miranda A., Borrayo-Sánchez G.: The Glu298Asp polymorphism of the endothelial nitric oxide synthase gene is associated with premature ST elevation myocardial infar­ction in Mexican population. Clin. Chim. Acta, 2010; 411: 553–557
  Google Scholar
• 11. Jiménez-Morales A.I., Ruano J., Delgado-Lista J., Fernandez J.M., Camargo A., López-Segura F., Villarraso J.C., Fuentes Jiménez F., Lo­pez-Miranda J., Pérez-Jiménez F.: NOS3 Glu298Asp polymorphism interacts with virgin olive oil phenols to determine the postpran­dial endothelial function in patients with the metabolic syndrome. J. Clin. Endocrinol. Metab., 2011; 96: e1694–e1702
  Google Scholar
• 12. Li H., Förstermann U.: Nitric oxide in the pathogenesis of vas­cular disease. J. Pathol., 2000; 190: 244–254
  Google Scholar
• 13. Li J., Wu X., Li X., Feng G., He L., Shi Y.: The endothelial nitric oxide synthase gene is associated with coronary artery disease: A meta-analysis. Cardiology, 2010; 116: 271–278
  Google Scholar
• 14. Magro M., Nauta S.T., Simsek C., Boersma E., van der Heide E., Regar E., van Domburg R.T., Zijlstra F., Serruys P.W., van Geuns R.J.: Usefulness of the SYNTAX score to predict “no reflow” in pa­tients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial in farction. Am. J. Cardiol., 2012; 109: 601–606
  Google Scholar
• 15. Naber C.K., Baumgart D., Altmann C., Siffert W., Erbel R., Heus­ch G.: eNOS 894T allele and coronary blood flow at rest and during adenosine-induced hyperemia. Am. J. Physiol. Heart Circ. Physiol., 2001; 281: 1908–1912
  Google Scholar
• 16. Niccoli G., Marino M., Spaziani C., Crea F.: Prevention and treat­ment of no-reflow. Acute Card. Care, 2010; 12: 81–91
  Google Scholar
• 17. Piana R.N., Paik G.Y., Moscucci M., Cohen D.J., Gibson C.M., Ku­gelmass A.D., Carrozza J.P. Jr., Kuntz R.E., Baim D.S.: Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation, 1994; 89: 2514–2518
  Google Scholar
• 18. Rezkalla S.H., Dharmashankar K.C., Abdalrahman I.B., Kloner R.A.: No-reflow phenomen on following percutaneous coronary in­tervention for acute myocardial infarction: Incidence, outcome and effect of pharmacologic therapy. J. Interv. Cardiol. 2010; 23: 429–436
  Google Scholar
• 19. Rezkalla S.H., Kloner R.A.: No-reflow phenomenon. Circulation, 2002; 105: 656–662
  Google Scholar
• 20. Rossi G.P., Taddei S., Wirdis A., Cavallin M., Ghiadoni L., Favilla S., Versari D., Sudano I., Pessina A.C., Salvetti A.: The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene af­fect the forearm blood flow responses of Caucasian hypertensive patients. J. Am. Coll. Cardiol., 2003; 41: 938–945
  Google Scholar
• 21. Sahin D.Y., Gür M., Elbasan Z., Kuloğlu O., Şeker T., Kivrak A., Tanboğa İ.H., Gözübüyük G., Kirim S., Çayli M.: SYNTAX score is a predictor of angiographic no-reflow in patients with ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention. Coron. Artery Dis., 2013; 24: 148–153
  Google Scholar
• 22. Saini V., Bhatnagar M.K., Bhattacharjee J.: Association of en­dothelial dysfunction with endothelin, nitric oxide and eNOS Glu­298Asp gene polymorphism in coronary artery disease. Dis. Markers, 2011; 31: 215–222
  Google Scholar
• 23. Sianos G., Morel M.A., Kappetein A.P., Morice M.C., Colombo A., Dawkins K., van den Brand M., Van Dyck N., Russell M.E., Mohr F.W., Serruys P.W.: The SYNTAX Score: An angiographic tool grad­ing the complexity of coronary artery disease. EuroIntervention, 2005; 1: 219–227
  Google Scholar
• 24. Tangürek B., Özer N., Sayar N., Terzi S., Yilmaz H.Y., Asiltürk R., Aksu H., Çiloğlu F., Aksoy Ş., Çağıl A.: The relationship between en­dothelial nitric oxide synthase gene polymorphism (T-786 C) and coronary artery disease in a Turkish population. Arch. Turk. Soc. Cardiol., 2005; 33: 467–472
  Google Scholar
• 25. Tanzilli G., Greco C., Pasceri V., Pelliccia F., Arrivi A., Placanica A., Mangieri E.: Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. Cathand. Card. Interven., 2010; 76: 787–793
  Google Scholar
• 26. Tian G.X., Zeng X.T., Wang X.B., Zhang L., Zhang W., Wei W.L.: Association between the endothelial nitric oxide synthase gene Glu­298Asp polymorphism and coronary heart disease: a meta‑analysis of 39 case‑control studies. Mol. Med. Rep., 2013; 7: 1310–1318
  Google Scholar
• 27. TIMI Study Group: The thrombolysis in myocardial ınfarction (TIMI) trial. Phase I findings. N. Engl. J. Med., 1985; 312: 932–936
  Google Scholar
• 28. Yoshimura M., Yasue H., Nakayama M., Shimasaki Y., Sumida H., Sugiyama S., Kugiyama K., Ogawa H., Ogawa Y., Saito Y., Miyamoto Y., Nakao K.: A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japa­nese. Hum. Genet., 1998; 103: 65–69
  Google Scholar
• 29. Zhao J.L., Yang Y.J., You S.J., Jing Z.C., Wu Y.J., Yang W.X., Chen J.L., Gao R. L., Chen Z. J.: Effect of adenosine on endothelin-1 in the infarcted reflow and no-reflow myocardium of mini-swine. Zhong­guoYi Xue Ke Xue Yuan Xue Bao, 2006; 28: 225–229
  Google Scholar

Pełna treść artykułu